These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 35261318)

  • 1. Effect of siponimod on magnetic resonance imaging measures of neurodegeneration and myelination in secondary progressive multiple sclerosis: Gray matter atrophy and magnetization transfer ratio analyses from the EXPAND phase 3 trial.
    Arnold DL; Piani-Meier D; Bar-Or A; Benedict RH; Cree BA; Giovannoni G; Gold R; Vermersch P; Arnould S; Dahlke F; Hach T; Ritter S; Karlsson G; Kappos L; Fox RJ;
    Mult Scler; 2022 Sep; 28(10):1526-1540. PubMed ID: 35261318
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
    Cree BA; Arnold DL; Fox RJ; Gold R; Vermersch P; Benedict RH; Bar-Or A; Piani-Meier D; Rouyrre N; Ritter S; Kilaru A; Karlsson G; Giovannoni G; Kappos L
    Mult Scler; 2022 Sep; 28(10):1591-1605. PubMed ID: 35380078
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Siponimod vs placebo in active secondary progressive multiple sclerosis: a post hoc analysis from the phase 3 EXPAND study.
    Gold R; Piani-Meier D; Kappos L; Bar-Or A; Vermersch P; Giovannoni G; Fox RJ; Arnold DL; Benedict RHB; Penner IK; Rouyrre N; Kilaru A; Karlsson G; Ritter S; Dahlke F; Hach T; Cree BAC
    J Neurol; 2022 Sep; 269(9):5093-5104. PubMed ID: 35639197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
    Cohan SL; Benedict RHB; Cree BAC; DeLuca J; Hua LH; Chun J
    CNS Drugs; 2022 Jul; 36(7):703-719. PubMed ID: 35725892
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Age independently affects myelin integrity as detected by magnetization transfer magnetic resonance imaging in multiple sclerosis.
    Newbould RD; Nicholas R; Thomas CL; Quest R; Lee JS; Honeyfield L; Colasanti A; Malik O; Mattoscio M; Matthews PM; Sormani MP; Waldman AD; Muraro PA
    Neuroimage Clin; 2014; 4():641-8. PubMed ID: 24936415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Tissue damage detected by quantitative gradient echo MRI correlates with clinical progression in non-relapsing progressive MS.
    Xiang B; Brier MR; Kanthamneni M; Wen J; Snyder AZ; Yablonskiy DA; Cross AH
    Mult Scler; 2022 Sep; 28(10):1515-1525. PubMed ID: 35196933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Higher EBV response is associated with more severe gray matter and lesion pathology in relapsing multiple sclerosis patients: A case-controlled magnetization transfer ratio study.
    Jakimovski D; Ramanathan M; Weinstock-Guttman B; Bergsland N; Ramasamay DP; Carl E; Dwyer MG; Zivadinov R
    Mult Scler; 2020 Mar; 26(3):322-332. PubMed ID: 30755085
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
    Hua LH; Bar-Or A; Cohan SL; Lublin FD; Coyle PK; Cree BA; Meng X; Su W; Cox GM; Fox RJ
    Mult Scler Relat Disord; 2023 Jul; 75():104766. PubMed ID: 37245350
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of ibudilast on thalamic magnetization transfer ratio and volume in progressive multiple sclerosis.
    Nakamura K; Zheng Y; Mahajan KR; Cohen JA; Fox RJ; Ontaneda D
    Mult Scler; 2023 Sep; 29(10):1257-1265. PubMed ID: 37537928
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study.
    Kappos L; Bar-Or A; Cree BAC; Fox RJ; Giovannoni G; Gold R; Vermersch P; Arnold DL; Arnould S; Scherz T; Wolf C; Wallström E; Dahlke F;
    Lancet; 2018 Mar; 391(10127):1263-1273. PubMed ID: 29576505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patterns of brain atrophy in recently-diagnosed relapsing-remitting multiple sclerosis.
    Meijboom R; York EN; Kampaite A; Harris MA; White N; Valdés Hernández MDC; Thrippleton MJ; MacDougall NJJ; Connick P; Hunt DPJ; Chandran S; Waldman AD;
    PLoS One; 2023; 18(7):e0288967. PubMed ID: 37506096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regional patterns of grey matter atrophy and magnetisation transfer ratio abnormalities in multiple sclerosis clinical subgroups: a voxel-based analysis study.
    Mallik S; Muhlert N; Samson RS; Sethi V; Wheeler-Kingshott CA; Miller DH; Chard DT
    Mult Scler; 2015 Apr; 21(4):423-32. PubMed ID: 25145689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unraveling the heterogeneous pathological substrates of relapse-onset multiple sclerosis: a multiparametric voxel-wise 3 T MRI study.
    Margoni M; Pagani E; Preziosa P; Gueye M; Azzimonti M; Rocca MA; Filippi M
    J Neurol; 2023 Aug; 270(8):3839-3850. PubMed ID: 37093395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease.
    Vrenken H; Pouwels PJ; Ropele S; Knol DL; Geurts JJ; Polman CH; Barkhof F; Castelijns JA
    Mult Scler; 2007 Jul; 13(6):708-16. PubMed ID: 17613597
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single scan quantitative gradient recalled echo MRI for evaluation of tissue damage in lesions and normal appearing gray and white matter in multiple sclerosis.
    Xiang B; Wen J; Cross AH; Yablonskiy DA
    J Magn Reson Imaging; 2019 Feb; 49(2):487-498. PubMed ID: 30155934
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fast whole-brain three-dimensional macromolecular proton fraction mapping in multiple sclerosis.
    Yarnykh VL; Bowen JD; Samsonov A; Repovic P; Mayadev A; Qian P; Gangadharan B; Keogh BP; Maravilla KR; Jung Henson LK
    Radiology; 2015 Jan; 274(1):210-20. PubMed ID: 25208343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gray matter atrophy in multiple sclerosis: a longitudinal study.
    Fisher E; Lee JC; Nakamura K; Rudick RA
    Ann Neurol; 2008 Sep; 64(3):255-65. PubMed ID: 18661561
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Central nervous system atrophy predicts future dynamics of disability progression in a real-world multiple sclerosis cohort.
    Tsagkas C; Naegelin Y; Amann M; Papadopoulou A; Barro C; Chakravarty MM; Gaetano L; Wuerfel J; Kappos L; Kuhle J; Granziera C; Sprenger T; Magon S; Parmar K
    Eur J Neurol; 2021 Dec; 28(12):4153-4166. PubMed ID: 34487400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multiparameter MRI quantification of microstructural tissue alterations in multiple sclerosis.
    Lommers E; Simon J; Reuter G; Delrue G; Dive D; Degueldre C; Balteau E; Phillips C; Maquet P
    Neuroimage Clin; 2019; 23():101879. PubMed ID: 31176293
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of volumetric MRI measures and disability in MS patients of the same age: Descriptions from a birth year cohort.
    de Ruiter LRJ; Loonstra FC; Jelgerhuis JR; Coerver EME; Toorop AA; van Leeuwen ICE; Noteboom S; Moraal B; Strijbis EMM; Schoonheim MM; Uitdehaag BMJ
    Mult Scler Relat Disord; 2023 Mar; 71():104568. PubMed ID: 36805177
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.